- Trial phase
- Phase 1
- Time to market
- Unknown, the drug is in early Phase 1 dose-escalation. Assuming successful development, a potential approval would be several years away (likely 2029+).
- Why 4/10
- FHD-909 is in Phase 1 dose-escalation with no specific dated binary catalyst (PDUFA, pivotal readout, or announced data-readout date) scheduled in the next ~12 months. The next hard catalyst would be Phase 1 clinical data, but no date has been set. Per the rubric, a Phase 1 drug without a dated binary within 12 months scores 4.
Monitor for any announced Phase 1 data readout date or interim results from the FHD-909 dose-escalation trial, which would be the next major catalyst. Also watch the December 2026 Lilly collaboration term expiration for potential restructuring or milestone news. The stock's ~144% implied upside to analyst targets reflects optimism about the platform, but early-stage clinical risk remains substantial.
Price Chart
Executive Summary
FHD-909 (LY4050784) is a selective SMARCA2 inhibitor in Phase 1 dose-escalation for SMARCA4-mutant cancers, primarily NSCLC, developed by Foghorn Therapeutics (Nasdaq: FHTX) in partnership with Eli Lilly. Preclinical data at AACR 2026 showed promising complete tumor regression in combination with anti-PD-1. The stock trades at ~$4.92 with a strong-buy analyst consensus and a mean $11.44 price target. However, the drug is early-stage with no human efficacy data yet, the Lilly collaboration term expires in December 2026, and another pipeline program (CBPd-171) recently hit a delay, making FHD-909 a high-risk/high-potential asset without a near-term binary catalyst.
How It Works
FHD-909 is a selective SMARCA2 inhibitor, an oral targeted cancer therapy. It exploits a genetic vulnerability: certain cancers (especially non-small cell lung cancer) lose the SMARCA4 gene and become dependent on its close cousin SMARCA2 to survive. By blocking SMARCA2, FHD-909 selectively kills SMARCA4-mutant cancer cells while sparing normal cells. Preclinical data also suggest it works well with immunotherapy (anti-PD-1).
Trial Status
FHD-909 is in a Phase 1 dose-escalation trial targeting SMARCA4 (BRG1)-mutant cancers, primarily non-small cell lung cancer (NSCLC). The trial was reported as "on track" and "advancing as planned" in Foghorn's Q2 2026 earnings update (August 2026). Preclinical data presented at AACR 2026 showed complete and durable tumor regression in combination with anti-PD-1 in mouse models, along with anti-tumor immune memory.
The Two-Sided Case
Upcoming Catalysts
- Phase 1 dose-escalation data readout (no specific date announced yet)
- Lilly collaboration research term expiration (December 2026), could trigger partnership restructuring or milestone payments
- Potential clinical data updates at future medical conferences
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Foghorn Therapeutics Inc. 8-K FHTX ·Originating report